ACT Capital Management’s Verona Pharma VRNA Stock Holding History

ACT Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.47M	Buy	+143,500	New	+$1.21M	2.02%	14

Other funds holding VRNA

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

ACT Capital Management's VRNA Position: Q3 2022 in Review

ACT Capital Management opened a new position in Verona Pharma (VRNA) in Q3 2022: 143,500 shares worth $1.47M. The stake represents 2.02% of the portfolio and ranks #14 among its holdings.

68 funds tracked by Wall St. Rank hold VRNA as of Q3 2022.

ACT Capital Management held 143,500 shares of Verona Pharma worth $1.47M as of Q3 2022.
Verona Pharma was a new ACT Capital Management position in Q3 2022.
Verona Pharma made up 2.02% of ACT Capital Management's portfolio in Q3 2022, its #14 holding.
68 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.